This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
TG Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
Axsome Therapeutics Q1 Adj. EPS $(0.68) Beats $(1.33) Estimate, Sales $121.46M Beat $119.87M Estimate
TG Therapeutics GAAP EPS of $0.03 Misses by $0.14, Revenue of $120.86M Beats by $3M
Morgan Stanley Upgrades Ascendis Pharma to Overweight, Raises Price Target to $250
Earnings Scheduled For May 5, 2025
Here's the Major Earnings Before the Open Tomorrow
Notable Healthcare Headlines for the Week: Gilead, CVS Health, Sanofi in Focus
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Ascendis Pharma Analyst Ratings
Ascendis Pharma Q1 EPS $(1.66) Misses $(1.46) Estimate, Sales $106.16M Beat $94.64M Estimate
Earnings Scheduled For May 1, 2025
A Glimpse of Ascendis Pharma's Earnings Potential
BridgeBio Pharma Analyst Ratings
HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47
SpringWorks Therapeutics Analyst Ratings
Sage Therapeutics Analyst Ratings
Earnings Call Summary | Sage Therapeutics(SAGE.US) Q1 2025 Earnings Conference
Earnings Call Summary | BridgeBio Pharma(BBIO.US) Q1 2025 Earnings Conference
Kiniksa Pharmaceuticals Analyst Ratings